real peptides FAQ

These are direct REV-ERB effects. The receptors control circadian rhythm and thermogenesis pathways. If sleep latency increases or body temperature feels dysregulated, shift administration time earlier by 2 hours and reduce dose by 20%. REV-ERB activation suppresses BMAL1, a core circadian clock gene; excessive suppression desynchronizes sleep-wake cycles. Persistent symptoms beyond 5 days at reduced dose indicate individual sensitivity to circadian modulation. Discontinue and complete full washout before considering protocol restart at lower dose.

This is a definitive red flag indicating the peptide was not synthesized under verifiable quality control or the supplier is reselling repackaged product without testing. HPLC (high-performance liquid chromatography) is the gold standard for peptide purity verification. Any legitimate manufacturer maintains these records for every batch and can produce them on request within one business day. If a vendor delays or offers generic COAs without batch-specific data, source from a supplier with transparent third-party testing like Real Peptides.

Discard it immediately. Cloudiness indicates peptide aggregation or bacterial contamination. Both render the solution unsafe and ineffective. Properly reconstituted DSIP is crystal clear with no visible particles or turbidity. Aggregated peptides cannot bind opioid receptors effectively because the tertiary protein structure required for receptor interaction has collapsed. Bacterial contamination introduces endotoxins that trigger inflammatory responses, directly contradicting the anti-inflammatory mechanism DSIP is meant to achieve.

Real Peptides offers custom synthesis for novel sequences or non-standard modifications. Request a quote through the website with the desired amino acid sequence, purity requirements, and quantity. Custom synthesis timelines typically range from 4–8 weeks depending on sequence complexity and required purification levels. All custom batches undergo the same third-party testing standards as catalog products, with full COA documentation provided before shipment.

Discard it. Protein denaturation at ambient temperature (20–25°C) is irreversible. The peptide structure cannot refold even if returned to proper storage. A four-hour excursion reduces potency by an estimated 50–70%, turning your injection into a low-dose or inactive solution. The financial loss is real, but using degraded peptide wastes both the dose and your research timeline. Temperature-controlled storage is non-negotiable with all peptides in our research collection.

Recalibrate or replace the refrigerator. The upper bound of acceptable storage is 8°C. A refrigerator running at 10°C is already outside the stability window. Chronic exposure to 10°C reduces the effective use window from 28 days to approximately 18–21 days. If recalibration isn't immediately possible, reduce your storage duration proportionally: use reconstituted Cartalax within 14–18 days instead of 28, and store vials in the coldest section of the refrigerator (typically the back of the lowest shelf, away from the door).

Use a validated cold chain container. An insulated cooler with gel ice packs pre-chilled to 2–4°C. Place the peptide vial in the centre of the cooler, surrounded by ice packs on all sides, and monitor temperature with a data logger if transport duration exceeds 2 hours. Peptides can tolerate brief excursions to 12–15°C (under 30 minutes), but sustained exposure above 10°C during transport accelerates degradation. If transport takes longer than 4 hours, consider whether it's more practical to reconstitute fresh peptide at the destination lab rather than risk thermal instability in transit.

This can indicate a Jarisch-Herxheimer-like response as immune regulation shifts and cytokine profiles normalise. Or it signals ongoing mold exposure overwhelming the therapy. Verify your environment first: repeat ERMI testing or inspect for hidden water damage. If environmental verification is clear, reduce the dose to 25mcg four times daily and increase by 12.5mcg weekly until you reach 50mcg without symptom exacerbation. Some patients require 6–8 weeks of low-dose therapy before tolerating full therapeutic doses.

This is the pattern with SS-31: rodent studies use 1–5mg/kg/day, but the only chronic human trial (MMPOWER-3) tested 40mg/day (0.57mg/kg). The discrepancy reflects conservative Phase 2 dose selection, not evidence that higher doses are unsafe. MMPOWER-3's pharmacokinetic analysis showed steady-state plasma concentrations of 80–120ng/mL. Measurably below the 150–200ng/mL achieved with acute IV dosing in TACTIC-HCM, which did produce functional cardiac changes. The implication: 40mg/day may represent a floor, not a ceiling, for chronic efficacy. Research protocols aiming to replicate preclinical benefits should consider doses in the 60–100mg/day range with twice-daily administration.

Administer the missed dose as soon as you remember if fewer than 3 days have passed since the scheduled injection, then resume your normal schedule. If more than 3 days have passed, skip the missed dose entirely and continue with the next planned injection. Do not double-dose to compensate. Missing 1–2 doses across a 15–20 injection cycle minimally impacts thymulin upregulation, but skipping an entire week disrupts the cumulative immune reconstitution pattern.

This signals receptor saturation. Reduce dose by 25% for the final week rather than increasing it. Plateaus at week 3 are normal; they indicate you've reached the upper limit of mitochondrial adaptation your current receptor density can support. Pushing dose higher accelerates desensitization without producing additional gains. The washout period following this cycle allows receptor density to normalize before the next active phase. Researchers who respond to plateaus by escalating dose report diminished returns in subsequent cycles.

Continue only if you're operating under medical supervision with regular bloodwork monitoring liver function, kidney function, and inflammatory markers. Six months falls within the timeframe covered by primate studies showing no toxicity signals, but you're now entering uncharted territory. Schedule comprehensive metabolic panels every 8–12 weeks. Look specifically for trends in ALT, AST, creatinine, and CRP rather than waiting for values to exceed normal ranges.

DSIP does not produce subjective sedation or immediate sleep sensation changes. Its primary effect is architectural. If you're not tracking sleep with objective measures (actigraphy, polysomnography, or consumer sleep trackers that measure sleep stages), you may not perceive the delta-wave enhancement. The peptide increases slow-wave sleep percentage and reduces sleep fragmentation. Changes that improve recovery markers but don't necessarily 'feel' different night-to-night. Verify your reconstitution concentration, injection timing, and storage conditions before concluding non-response.

Administer the missed dose as soon as you remember if fewer than 12 hours have passed since the scheduled time. If more than 12 hours have passed, skip the missed dose and resume on the next scheduled day. Do not double-dose. DSIP's modulatory effects persist 18–24 hours, so a single missed dose typically does not erase prior receptor upregulation. However, missing two consecutive doses may reduce pain threshold improvements by 20–30% based on washout kinetics in published studies.

This is uncommon but not unheard of. Transient cytokine elevation can occur as IRR activation initially upregulates certain inflammatory pathways before downregulating them. If serum TNF-α or IL-6 rises during weeks 1–2 but symptoms remain stable or improve, continue the protocol and recheck markers at week 4. If both markers and symptoms worsen, discontinue and consult the overseeing research protocol guidelines. This may indicate a paradoxical inflammatory response that occurs in fewer than 5% of cases based on anecdotal research reports.

DSIP occupies a unique niche. It's not a growth hormone secretagogue like MK 677, not a tissue repair peptide like BPC-157, and not a direct nootropic like Dihexa. Its primary value is in hypothalamic modulation and cortisol management. Comparative protocols should measure cortisol suppression duration, slow-wave sleep architecture, and inflammatory cytokine clearance rather than muscle protein synthesis or wound healing. The outcomes DSIP influences most directly.

Mild injection site redness, slight swelling, or transient fatigue within 12–24 hours post-injection are common immune activation responses. They indicate thymulin upregulation and cytokine rebalancing, not an adverse reaction. These symptoms typically resolve within 48 hours and diminish in intensity as the cycle progresses. If symptoms persist beyond 72 years or worsen with each injection, reduce dose to 5mg and extend frequency to once every 4 days rather than 2–3 times weekly.

Administer the missed dose as soon as you remember if fewer than 12 hours have passed since the scheduled evening administration, then resume the regular schedule the following day. If more than 12 hours have elapsed, skip the missed dose entirely and continue with the next scheduled dose. Do not double-dose to compensate. Missing 1–2 doses during a 20-day cycle has minimal impact on overall transcriptional outcomes, but missing 4+ doses or clustering missed doses in the first week significantly reduces endpoint measurements of mucin production and TFF expression.

DSIP's mechanism is non-GABAergic and non-serotonergic, meaning it doesn't overlap with benzodiazepines, Z-drugs, or melatonin pathways. Combining DSIP with magnesium glycinate, L-theanine, or low-dose melatonin (0.3–0.5mg) is mechanistically sound. Each acts on different sleep-regulatory systems. Avoid combining DSIP with GABAergic sedatives (Ambien, Lunesta) in research settings without documented protocol justification. While no direct contraindication exists, layering multiple CNS-active compounds complicates attribution of effects. If you're using other peptides with metabolic or hormonal effects. Like MK-677 for GH secretion or Thymalin for immune modulation. Timing matters. MK-677 increases GH pulse amplitude during slow-wave sleep, so administering it alongside DSIP may enhance the restorative phase DSIP extends. Document everything: peptide interactions in research are under-studied compared to small-molecule drugs. The biggest protocol error we see: researchers dose DSIP inconsistently. 1mg one night, 0.5mg the next, then skipping two nights. And expect stable results. Sleep architecture modulation compounds over consecutive nights. A single dose produces measurable changes; sustained nightly use for 14+ days shows cumulative benefit. If you're serious about using DSIP for sleep quality protocol, commit to the timeline and the precision.

Administer the missed dose as soon as you remember. Up to 12 hours past the scheduled time. Then resume the regular schedule. If more than 12 hours have passed, skip the missed dose entirely and continue with the next scheduled administration. Do not double-dose to compensate. ARA-290's mechanism relies on sustained receptor activation over consecutive days; missing a single dose reduces cumulative effect but doesn't negate prior doses. However, missing multiple doses (e.g., two consecutive days in a 7-day protocol) significantly attenuates outcomes because the M1-to-M2 macrophage shift requires consistent signaling to maintain the polarised state. If you miss more than one dose in a row, consider extending the protocol by the number of missed days rather than stopping at the original endpoint.